Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

167.70
+1.010.61%
Post-market: 167.710.0050+0.00%18:24 EDT
Volume:17.55M
Turnover:2.96B
Market Cap:403.76B
PE:28.96
High:169.90
Open:167.48
Low:167.05
Close:166.69
Loading ...

Stock Market Drama Highlights Trump's Game Of Chicken With Economy

Blockhead
·
07 Mar

BUZZ-Neumora's IPO bookrunner Stifel cuts to 'hold' after J&J setback

Reuters
·
07 Mar

Johnson & Johnson Unit's Lazertinib With Amivantamab Approved in UK for Non-Small Cell Lung Cancer

MT Newswires Live
·
07 Mar

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

Dow Jones
·
07 Mar

J&J to stop late-stage study of add-on depression drug

Reuters
·
07 Mar

J&J - Will Explore Future Development Opportunities for Aticaprant in Other Areas of High Unmet Need

THOMSON REUTERS
·
07 Mar

J&J - Johnson & Johnson Has Made the Decision to Discontinue the Phase 3 Ventura Development Program

THOMSON REUTERS
·
07 Mar

Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Dow Jones
·
07 Mar

Big Pharma wants to bring back a tax break that could save it $15 billion

Quartz
·
07 Mar

Pfizer appoints former J&J executive to lead obesity drug development

Reuters
·
07 Mar

Is Johnson & Johnson (JNJ) the Best Holding Company Stock to Buy Right Now?

Insider Monkey
·
07 Mar

BRIEF-UK's MHRA Approves Lazertinib For Use With Amivantamab For Non-Small Cell Lung Cancer Treatment

Reuters
·
07 Mar

UK's Mhra: Lazertinib Approved for Use in Combination With Amivantamab for Treatment of Adults With Non-Small Cell Lung Cancer

THOMSON REUTERS
·
07 Mar

2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid

Motley Fool
·
06 Mar

FACTBOX-Trump's tariffs and threatened trade actions

Reuters
·
06 Mar

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Business Wire
·
06 Mar